Pharmacological and lifestyle factors modulating serum paraoxonase-1 activity

Mini-Reviews in Medicinal Chemistry

Volumn 9, Issue 8, 2009, Pages 911-920

  Camps, Jordi ^a   Marsillach, Judit ^a   Joven, Jorge ^a  

^a HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

Author keywords

Apolipoprotein A I; Fibrates; High density lipoproteins; Lipid peroxidation; Nutrition; Paraoxonase 1; Rosiglitazone; Statins

Indexed keywords

ABC TRANSPORTER A1; AMLODIPINE; ANTIRETROVIRUS AGENT; APOLIPOPROTEIN A1; ARYLDIALKYLPHOSPHATASE 1; ATORVASTATIN; BEZAFIBRATE; CERIVASTATIN; CIPROFIBRATE; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTERASE; FENOFIBRATE; FLUINDOSTATIN; GEMFIBROZIL; GLUCONOLACTONASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; MEVINOLIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PITAVASTATIN; PLACEBO; PRAVASTATIN; ROSIGLITAZONE; ROSUVASTATIN; SIMVASTATIN; STEROL REGULATORY ELEMENT BINDING PROTEIN; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL; UNINDEXED DRUG;

ALCOHOL CONSUMPTION; ANTIOXIDANT ACTIVITY; CARDIOVASCULAR DISEASE; CHOLESTEROL DIET; CLINICAL TRIAL; DIETARY INTAKE; DISEASE PREDISPOSITION; DRUG STRUCTURE; DYSLIPIDEMIA; ENVIRONMENTAL FACTOR; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; ENZYME STRUCTURE; FATTY LIVER; FOOD COMPOSITION; GENE EXPRESSION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; LIFESTYLE; LIPODYSTROPHY; MEDITERRANEAN DIET; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PROMOTER REGION; PROTEIN BINDING; RECEPTOR UPREGULATION; REVIEW; TREATMENT OUTCOME; UPREGULATION; VITAMIN SUPPLEMENTATION; WEIGHT REDUCTION;

EID: 70349109252     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/138955709788681591     Document Type: Review

References (112)

1. Primo-Parmo, S.L.; Sorenson, R.C.; Teiber, J.; La Du, B.N. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics, 1996, 33, 498-507.
2. Sorenson, R.C.; Primo-Parmo, S.L.; Camper, S.A.; La Du, B.N. The genetic mapping and gene structure of mouse paraoxonase/arylesterase. Genomics, 1995, 30, 431-8.
3. La Du, B.N. In Pharmacogenetics of Drug Metabolism; Kalow Ed.; Pergamon Press: New York, 1992; pp. 51-91.
4. Leviev, I.; Negro, F.; James, R.W. Two alleles of the human paraoxonase gene produce different amounts of mRNA. Arterioscler. Thromb. Vasc. Biol., 1997, 17, 2935-9.
5. Sierksma, A.; van der Gaag, M.S.; van Tol, A.; James, R.W.; Hendriks, F.J. Kinetics of HDL cholesterol and paraoxonase activity in moderate alcohol consumers. Alcohol. Clin. Exp. Res., 2002, 26, 1430-5.
6. Jaouad, L.; de Guise, C.; Berrougui, H.; Cloutier, M.; Isabelle, M.; Fulop, T.; Pavette, H.; Khalil, A. Age-related decreased in highdensity lipoproteins antioxidant activity is due to an alteration in the PON1's free sulfhydryl groups. Atherosclerosis, 2006, 185, 191-200.
7. Ng, C.J.; Wadleigh, D.J., Gangopadhyay, A.; Hama, S.; Grijalva, V.R.; Navab, M.; Fogelman, A.M.; Reddy, S.T. Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J. Biol., Chem., 2001, 276, 44444-9.
8. Billecke, S.; Draganov, D.; Counsell, R.; Stetson, P.; Watson, C.; Hsu, C.; La Du, BN. Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug. Metab. Dispos., 2000, 28, 1335-42.
9. Costa, L.G., Cole, T.B.; Vitalone, A.; Furlong, C.E. Measurement of paraoxonase (PON1) status as a potential biomarker of susceptibility to organophosphate toxicity. Clin. Chim. Acta, 2005, 352, 37-47.
10. Draganov, D.I.; Teiber, J.F.; Speelman, A.; Osawa, Y.; Sunahara, R.; La Du, B.N. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J. Lipid Res., 2005, 46, 1239-47.
11. Aviram, M.; Rosenblat, M. Paraoxonases 1, 2, and 3, oxidative stress, and macrophage cell formation during atherosclerosis development. Free Radic. Biol. Med., 2004, 37, 1304-16.
12. Horke, S.; Witte, I..; Wilgenbus, P.; Krüger, M.; Strand, D.; Förstermann, U. Paraoxonase-2 reduces oxidative stress in vascular cells and decreases endoplasmic reticulum stress-induced caspase activation. Circulation, 2007, 115, 2055-64.
13. Mackness, B.; Mackness, M.I. In The Paraoxonases: Their Role in Disease Development and Xenobiotic Metabolism; Mackness, Mackness, Aviram, Paragh, Eds.; Springer: Dordrecht, 2008, pp. 51-60.
14. Marsillach, J.; Parra, S.; Ferré, N.; Coll, B.; Alonso-Villaverde, C.; Joven, J.; Camps, J. In The Paraoxonases: Their Role in Disease Development and Xenobiotic Metabolism; Mackness, Mackness, Aviram, Paragh, Eds.; Springer: Dordrecht, 2008, pp. 187-198.
15. Costa, L.G.; Cole, T.B.; Jarvik, G.P.; Furlong, C:E. Functional genomic of the paraoxonase (PON1) polymorphisms: effects on pesticide sensitivity, cardiovascular disease, and drug metabolism. Annu. Rev. Med., 2003, 54, 371-92.
16. Furlong, C.E.; Cole, T.B.; Jarvik, G.P.; Pettan-Brewer, C.; Geiss, G.K.; Richter, R.J; Shih, D.M.; Tward, A.D.; Lusis, A.J.; Costa, L.G. Role of paraoxonase (PON1) status in pesticide sensitivity: genetic and temporal determinants. Neurotoxicology, 2005, 26, 651-9.
17. Garin, M.C.; James, R.W.; Dussoix, P.; Blanché, H.; Passé, P.; Froguel, P.; Ruiz, J. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J. Clin. Invest., 1997, 99, 62-6.
18. Furlong, C.E.; Richter, R.J.; Li, W.F.; Brophy, V.H.; Carlson, C.; Rieder, M.; Nickerson, D.; Costa, L.G.; Ranchalis, J.; Lusis, A.J.; Shih, D.M.; Tward, A.; Jarvik, G.P. In The Paraoxonases: Their Role in Disease Development and Xenobiotic Metabolism; Mackness, Mackness, Aviram, Paragh, Eds.; Springer: Dordrecht, 2008; pp. 267-281.
19. Mackness, M.I.; Arrol, S.; Durrington, P.N. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett., 1991, 286, 152-4.
20. Mackness, M.I.; Arrol, S.; Abbott, C.A.; Durrington, P.N. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis, 1993, 104, 129-35.
21. Navab, M.; Berliner, J.A.; Watson, A.D.; Hama, S.Y.; Territo, M.C.; Lusis, A.J.; Shih, D.M.; Van Lenten, B.J.; Frank, J.S.; Demer. L.L.; Edwards, D.A.; Fogelman, A.M. The yin and yang of oxidation in the development of the fatty streak: a review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler. Thromb. Vasc. Biol., 1996, 16, 152-4.
22. Aviram, M.; Rosenblat, M.; Bisgaier, C.L.; Newton, R.S.; Primo-Parmo, S.L.; La Du, B.N. Paraoxonase inhibits high density lipoprotein (HDL) oxidation and preserves its functions: a possible peroxidative role for paraoxonase. J. Clin. Invest., 1998, 101, 1581-90.
23. Aviram, M,; Billecke, S.; Sorenson, R.; Bisgaier, C.; Newton, R.S.; Rosenblat, M.; Erogul, J.; Hsu, C.; Dunlop, C.; La Du, B.N. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler. Thromb. Vasc. Biol., 1998, 18, 1617-24.
24. Mackness, M.I.; Durrington, P.N.; Mackness, B. How high-density lipoprotein protects against the effects of lipid peroxidation. Curr. Opin. Lipidol., 2000, 11, 383-8.
25. Ahmed, Z.; Ravandi, A.; Maguire, G.F.; Emili, A.; Draganov, D.I.; La Du, B.N.; Kuksis, A.; Connelly, P.W. Apolipoprotein A-I pro motes the formation of phosphatidylcholine core aldehydes that are hydrolyzed by paraoxonase (pon-1) during high density lipoprotein oxidation with a peroxynitrite donor. J. Biol. Chem., 2001, 276, 24473-81.
26. Sanvanich, P., Mackness, B.; Gaskell, S.J.; Durrington, P.; Mackness, M. The effect of high-density lipoproteins on the formation of lipid/ protein conjugates during in vitro oxidation of low-density lipoprotein. Biochem. Biophys. Res. Commun., 2003, 300, 501-6.
27. Shih, D.M.; Gu, L.; Xia, Y.R., Navab, M.; Li, W.F.; Hama, S.; Castellani, L.W.; Furlong, C.E.; Costa, L.G.; Fogelman, A.M.; Lusis, A.J. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature, 1998, 394, 284-7.
28. Shih, D.M.; Xia, Y.R.; Miller, E.; Castellani, L.W.; Subbanagounder, G.; Cheroutre, H.; Faull, K.F.; Berliner, J.A.; Witztum, J.L.; Lusis, A.J. Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J. Biol. Chem., 2000, 275, 17527-35.
29. Tward, A.; Xia, Y.R.; Wang, X.P.; Shi, Y.S.; Park, C.; Castellani, L.W.; Lusis, A.J.; Shih, D.M. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation, 2002, 106, 484-90.
30. Oda, M.N.; Bielicki, J.K.; Ho, T.T.; Berger, T.; Rubin, E.M.; Forte, T.M. Paraoxonase 1 overexpression in mice and its effect of highdensity lipoproteins. Biochem. Biophys. Res. Commun., 2002, 290, 921-7.
31. Harel, M.; Aharoni, A.; Gaidukov, L.; Brumshtein, B.; Khersonsky, O.; Meged, R.; Dvir, H.; Ravelli, R.B.; McCarthy, A.; Toker, L.; Silman, I.; Sussman, J.L.; Tawfik, D.S. Structure and evolution of the human serum paraoxonase family of detoxifying and antiatherosclerotic enzymes. Nat. Struct. Mol. Biol. 2004, 11, 412-9.
32. Aharoni, A.; Gaidukov, L.; Yagur, S.; Toker, L.; Silman, I,; Tawfik, D.S. Directed evolution of mammalian paraoxonases PON1 and PON3 for bacterial expression and catalytic specialization. Proc. Natl. Acad. Sci. USA, 2004, 101, 482-7.
33. Aharoni, A.; Gaidukov, L.; Khersonsky, O.; McQGould, S.; Roodveldt, C.; Tawkif, D.S. The 'evolvability' of promiscuous protein functions. Nat. Genet., 2005, 37, 73-6.
34. Khersonsky, O.; Tawfik, D.S. Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry, 2005, 44, 6371-82.
35. Aharoni, A.; Amitai, G.; Bernath, K.; Magdassi, S.; Tawfik, D.S. High-throughput screening of enzyme libraries: thiolactonases evolved by fluorescence-activated sorting of single cells in emulsion compartments. Chem. Biol., 2005, 12, 1281-9.
36. Khersonsky, O.; Roodveldt, C.; Tawfik, D.S. Enzyme promiscuity: evolutionary and mechanistic aspects. Curr. Opin. Chem. Biol., 2006, 10, 498-508.
37. Khersonsky, O.; Tawfik, D.S. The histidine 115-histidine 134 mediates the lactonase activity of mammalian serum paraoxonases. J. Biol. Chem., 2006, 281, 7649-56.
38. Rosenblat, M.; Gaidukov, L.; Khersonsky, O.; Vaya, J.; Oren, R.; Tawfik, D.S.; Aviram, M. The catalytic histidine dyad of high density liproprotein-associated serum paraoxonase-1 (PON1) is essential for PON1-mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux. J. Biol. Chem., 2006, 182, 7657-65.
39. Camps, J.; Marsillach, J.; Joven, J. The paraoxonases: role in human diseases and methodological difficulties in measurement. Crit. Rev. Clin. Lab. Sci., 2009, 46, 83-106.
40. Saini, H.K.; Xu, Y.J.; Arneja, A.S.; Tappia, P.S.; Dhalla, N.S. Pharmacological basis of different targets for the treatment of atherosclerosis. J. Cell. Mol. Med., 2005, 9, 818-39.
41. Reinoso, R.F.; Sánchez Navarro, A.; García, M.J.; Prous, J.R. Preclinical pharmacokinetics of statins. Methods Find. Exp. Clin. Pharmacol., 2002, 24, 593-616.
42. Paragh, G.; Harangi, M.; Seres, I. In The Paraoxonases: Their Role in Disease Development and Xenobiotic Metabolism; Mackness, Mackness, Aviram, Paragh, Eds.; Springer: Dordrecht, 2008, pp. 251-266.
43. Davidson, M.H. Clinical significance of statin pleiotropic effects: hypotheses versus evidence. Circulation, 2005, 111, 2280-1.
44. Tomás, M.; Sentí, M.; García-Faria, F.; Vila, J.; Torrents, A.; Covas, M.; Marrugat, J. Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients. Arterioscler. Thromb. Vasc. Biol., 2000, 20, 2113-9.
45. Harangi, M.; Seres, I.; Varga, S.; Emri, G.; Szilvássy, Z.; Paragh, G.; Remenyik, E. Atorvastatin effect on high-density lipoprotein-associated paraoxonase activity and oxidative DNA damage. Eur. J. Clin. Pharmacol., 2004, 60, 685-91.
46. Kassai, A.; Illés, L.; Mirdamadi, H.Z.; Seres, I.; Kalmár, T.; Audikovszky, M.; Paragh, G. The effect of atorvastatin therapy on lecithin:cholesterol acyltrasnferase, cholesteryl ester transfer protein and the antioxidant paraoxonase. Clin. Biochem., 2007, 40, 1-5.
47. Bolayirli, I.M.; Aslan, M.; Balci, H.; Altug, T.; Hacibekiroglu, M.; Seven, A. Effects of atorvastatin therapy on hypercholesterolemic rabbits with respect to oxidative stress, nitric oxide pathway and homocysteine. Life Sci., 2007, 81, 121-7.
48. Bergheanu, S.C.; Van Tol, A.; Dallinga-Thie, G.M.; Liem, A.; Dunselman, P.H.; Van der Bom, J.G.; Jukema, J.W. Effect of rosuvastatin versus atorvastatin treatment on paraxonase-1 activity in men with established cardiovascular disease and a low HDLcholesterol. Curr. Med. Res. Opin., 2007, 23, 2235-40.
49. Mirdamadi, H.; Sztanek, F.; Derdak, Z.; Seres, I.; Harangi, M.; Paragh, G. The human paraoxonase-1 phenotype modifies the effect of statins on paraoxonase activity and lipid parameters. Br. J. Clin. Pharmacol., 2008, 66, 366-74.
50. Deakin, S.P.; James, R.W. In The Paraoxonases: Their Role in Disease Development and Xenobiotic Metabolism; Mackness, Mackness, Aviram, Paragh, Eds.; Springer: Dordrecht, 2008, pp. 241-250.
51. Deakin, S.P.; Leviev, I.; Guernier, D.; James, R.W. Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase activity: a role for sterol regulatory element-binding protein-2. Arterioscler. Thromb. Vasc. Biol., 2003, 23, 2083-9.
52. Durrington, P.N.; Mackness, M.I.; Bhatnagar, D.; Julier, K.; Prais, H.; Arrol, S.; Morgan, J.; Wood, G.N. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia. Atherosclerosis, 1998, 138, 217-25.
53. Tsimihodimos, V.; Kakafika, A.; Tambaki, A.P.; Bairaktari, E.; Chapman, M.J.; Elisaf, M.; Tselepis, A.D. Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins. J. Lipid Res., 2003, 44, 927-34.
54. Paragh, G.; Seres, I.; Balogh, Z.; Harangi, M.; Illyés, L.; Boda, J.; Varga, Z.S.; Kovács, P. The effect of micronised fenofibrate on serum paraoxonase activity in patients with coronary heart disease. Diabetes Metab., 2003, 29, 613-18.
55. Paragh, G.; Seres, I.; Harangi, M.; Erdei, A.; Audikovszky, M.; Debreczni, L.; Kovácsay, A. Ciprofibrate increases paraoxonase activity in patients with metabolic syndrome. Br. J. Clin. Pharmacol., 2006, 61, 694-701.
56. Ackerman, Z.; Oron-Herman, M.; Rosenthal, T.; Pappo, O.; Link, G.; Sela, B.A.; Grozovski, M. Effects of amlodipine, captopril, and bezafibrate on oxidative milieu in rats with fatty liver. Dig. Dis. Sci., 2008, 53, 777-84.
57. Phuntuwate, W.; Suthisisang, C.; Koanantakul, B.; Chaloeiphap, P.; Mackness, B.; Mackness, M. Effect of fenofibrate therapy on paraoxonase1 status in patients with low HDL-C levels. Atherosclerosis,, 2008, 196, 122-8.
58. Gouédard, C.; Koum-Besson, N.; Barouki, R.; Morel, R. Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofibrate and statins. Mol. Pharmacol., 2003, 63, 946-56.
59. Datta, G.; Chaddha, M.; Hama, S.; Navab, M.; Fogelman, A.M.; Garber, D.W.; Mishra, V.K.; Epand, R.M.; Epand, R.F.; Lund-Katz, S.; Phillips, M.C.; Segrest, J.P.; Anantharamaiah, G.M. Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide. J. Lipid Res., 2001, 42, 1096-1104.
60. Navab, M.; Anantharamaiah, G.M.; Reddy, S.T.; Hama, S.; Hough, G.; Grijalva, V.R.; Wagner, A.C.; Frank, J.S.; Datta, G.; Garber, D.; Fogelman, A.M. Oral D-4F causes formation of pre-β highdensity lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation, 2004, 109, 3215-20.
61. Navab, M.; Anantharamaiah, G.M.; Reddy, S.T.; Hama, S.; Hough, G.; Frank, J.S.; Grijalva, V.R.; Ganesh, V.K.; Mishra, V.K.; Palgunachari, M.N.; Fogelman, A.M. Oral small peptides render HDL antiinflammatory in mice and monkeys and reduce atherosclerosis in apo E null mice. Circ. Res., 2005, 97, 524-32.
62. Anantharamaiah, G.M.; Mishra, V.K.; Garber, D.W.; Datta, G.; Handattu, S.P.; Palgunachari, M.N.; Chaddha, M.; Navab, M.; Reddy, S.T.; Segrest, J.P.; Fogelman, A.M. Structural requirements for antioxidative and anti-inflammatory properties of apolipoprotein A-I mimetic peptides. J. Lipid Res., 2007, 48, 1915-23.
63. Van Lenten, B.J.; Wagner, A.C.; Anantharamaiah, G.M.; Hama, S.; Reddy, S.T.; Fogelman, A.M. Lipoprotein inflammatory properties and serum amyloid A levels but not cholesterol levels predict lesion area in cholesterol-fed rabbits. J. Lipid Res., 2007, 48, 2344-53.
64. Navab, M.; Anantharamaiah, G.M.; Reddy, S.T.; Van Lenten, B.J.; Buga, G.M.; Fogelman, A.M. Peptide mimetics of apolipoproteins improve HDL functions. J. Clin. Lipidol., 2007, 1, 142-7.
65. Bloedon, L.T.; Dunbar, R.; Duffy, D.; Pinell-Salles, P.; Norris, R.; DeGroot, B.J.; Movva, R.; Navab, M.; Fogelman, A.M.; Rader, D.J. Safety, parmacokinetics, and pharmacodynamics of oral apo A-I mimetic peptide D-4F in high risk cardiovascular patients. J. Lipid Res., 2008, 49, 1344-52.
66. Raskin, P.; Rappaport, E.B.; Cole, S.T.; Yan, Y.; Patwardhan, R.; Freed, M.I. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes. Diabetologia, 2000, 43, 278-84.
67. van Wijk, J.P.; de Koning, E.J.; Castro Cabezas, M.; Rabelink, T.J. Rosiglitazone improves postprandial triglyceride and free fatty acid metabolism in type 2 diabetes. Diabetes Care, 2005, 28, 844-9.
68. Chappuis, B.; Braun, M.; Stettler, C.; Allemann, S.; Diem, P.; Lumb, P.J.; Wierzbicki, A.S.; James, R.; Christ, E.R. Differential effect of pioglitazone (PGZ) and rosiglitazone (RGZ) on postprandial glucose and lipid metabolism in patients with type 2 diabetes mellitus: a prospective, randomized crossover study. Diabetes Metab. Res. Rev., 2007, 23, 392-9.
69. van Wijk, J.; Coll, B.; Castro Cabezas, M.; Koning, E.; Camps, J.; Rabelink, T.; Mackness, B.; Joven, J. Rosiglitazone modulates fasting and post-prandial paraoxonase 1 activity in type 2 diabetic patients. Clin. Exp. Pharmacol. Physiol., 2006, 33, 1134-7.
70. Mulligan, K.; Yang, Y.; Wininger, D.A.; Koletar, S.L.; Parker, R.A.; Alston-Smith, B.L.; Schouten, J.T.; Fielding, R.A.; Basar, M.T.; Grinspoon, S. Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio. AIDS, 2007, 21, 47-57.
71. Coll, B.; van Wijk, J.P.H.; Parra, S.; Castro Cabezas, M.; Hoepelman, I.M.; Alonso-Villaverde, C.; Koning, E.J.P.; Camps, J.; Ferré, N.; Rabelink, T.J.; Tous, M.; Joven, J. Effects of rosiglitazone and metformin on postprandial paraoxonase-1 and monocyte chemoattractant protein-1 in human immunodeficiency virus-infected patients with lipodystrophy. Eur. J. Pharmacol., 2006, 544, 104-10.
72. Couillard, C.; Ruel, G.; Archer, R.W.; Pomerleau, S.; Bergeron, J.; Couture, P.; Lamarche, B., Bergeron, N. Circulating levels of oxidative stress markers and endothelial adhesion molecules in men with abdominal obesity. J. Clin. Endocr. Metab., 2005, 90, 6454-9.
73. Tan, K.C.B.; Tso, A.W.K.; Tam, S.C.F.; Pang, R.W.C.; Lam, K.S.L. Acute effect of orlistat on post-prandial lipaemia and free fatty acids in overweight patients with type 2 diabetes mellitus. Diabetes Med., 2002, 19, 944-8.
74. Audikovszky, M.; Pados, G.; Seres, I.; Harangi, M.; Fülöp, P.; Katona, E.; Illyés, L.; Winkler, G.; Katona, E.M.; Paragh, G. Orlistat increases serum paraoxonase activity in obese patients. Nutr. Metab. Card. Dis., 2007, 17, 268-73.
75. Carr, M.C. The emergence of the metabolic syndrome with menopause. J. Clin. Endocr. Metab., 2003, 88, 2404-11.
76. Zago, V.; Sanguinetti, S.; Brites, F.; Berg, G.; Verona, J.; Basilio, F.; Wikinski, R.; Schreier, L. Impaired high density lipoprotein antioxidant activity in healthy postmenopausal women. Atherosclerosis, 2004, 177, 203-10.
77. Grady, D.; Rubin, S.M.; Petitti, D.B.; Fox, C.S.; Black, D.; Ettinger, B.; Ernster, V.L.; Cummings, S.R. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann. Intern. Med., 1992, 117, 1016-37.
78. Hulley, S.; Furberg, C.; Barrett-Connor, E.; Cauley, J.; Grady, D.; Haskell, W.; Knopp, R.; Lowery, M.; Satterfield, S.; Schrott, H.; Vittinghoff, E.; Hunninghake, D.; HERS Research Group. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/ progestin Replacement Study follow-up (HERS II). JAMA., 2002, 288, 58-66.
79. Sutherland, W.H.F.; Manning, P.J.; de Jong, S.A.; Allum, A.R.; Jones, S.D.; Williams, S.M. Hormone-replacement therapy increases serum paraoxonase arylesterase activity in diabetic postmenopausal women. Metabolism, 2001, 50, 319-324.
80. Topçuoglu, A.; Uzun, H.; Aydin, S.; Kahraman, N.; Vehid, S.; Zeybek, G.; Topçuoglu, D. The effect of hormone replacement therapy on oxidized low density lipoprotein levels and paraoxonase activity in postmenopausal women. Tohoku J. Exp. Med., 2005, 205, 79-86.
81. Kwok, S.; Selby, P.L.; Mc.Elduff, P.; Laing, I.; Mackness, B.; Mackness, M.I.; Prais, H.; Morgan, J.; Yates, A.P.; Durrington, P.M.; Sci, F.M. Progestogens of varying androgenicity and cardiovascular risk factors in postmenopausal women receiving oestrogen replacement therapy. Clin. Endocr., 2004, 61, 760-7.
82. Koh, K.K.; Han, H.S.; Ahn, J.Y.; Chung, Q.J.; Lee, Y.; Shin, E.K. Amlodipine improves endothelial function and metabolic parameters in patients with hypertension. Internat. J. Cardiol., 2009, 133, 23-31.
83. Malmqvist, K.; Kahan, T.; Isaksson, H.; Ostergren, J. Regression of left ventricular mass with captopril and metoprolol, and the effects on glucose and lipid metabolism. Blood Press., 2001, 10, 101-10.
84. Marsillach, J.; Martínez-Vea, A.; Marcas, L.; Mackness, B.; Mackness, M.; Ferré, N., Joven, J.; Camps, J. Administration of exogenous erythropoietin beta affects lipid peroxidation and serum paraoxonase-1 activity and concentration in predialysis patients with chronic renal disease and anaemia. Clin. Exp. Pharmacol. Physiol., 2007, 34, 347-9.
85. Hu, F.B.; Willet, W.C. Optimal diets for prevention of coronary heart disease. JAMA, 2002, 288, 2569-78.
86. Jarvik, G.P.; Tsai, N.T.; McKinstry, L.A.; Wani, R.; Brophy, V.H.; Richter, R.J.; Schellenberg, G.D.; Heagerty, P.J.; Hatsukami, T.S.; Furlong, C.E. Vitamin C and E intake is associated with increased paraoxonase activity. Arterioscler. Thromb. Vasc. Biol., 2002, 22, 1329-33.
87. Ferré, N.; Camps, J.; Fernández-Ballart, J.; Arija, V.; Murphy, M.M.; Ceruelo, S.; Biarnés, E.; Vilella, E.; Tous, M.; Joven, J. Regulation of serum paraoxonase activity by genetic, nutritional, and lifestyle factors in the general population. Clin. Chem., 2003, 49, 1491-7.
88. Kleemola, P.; Freese, R.; Jauhiainen, M.; Pahlman, R.; Alfthan, G.; Mutanen, M. Dietary determinants of serum paraoxonase activity in healthy humans. Atherosclerosis, 2002, 160, 425-32.
89. Nguyen, S.D.; Sok, D.E. Beneficial effect of oleoylated lipids on paraoxonase-1: protection against oxidative inactivation and stabilization. Biochem. J., 2003, 375, 275-85.
90. Tomàs, M.; Sentí, M.; Elosua, R.; Vila, J.; Sala, J.; Masia, R.; Marrugat, J. Interaction between the Gln-Arg 192 variants of the paraoxonase gene and oleic acid intake as a determinant of highdensity lipoprotein cholesterol and paraoxonase activity. Eur. J. Pharmacol., 2001, 432, 121-8.
91. Rosenblat, M.; Volkova, N.; Coleman, R.; Almagor, Y.; Aviram, M. Antiatherogenicity of extra virgin olive oil and its enrichment with green tea polyphenols in the atherosclerotic apolipoprotein-Edeficient mice: enhanced macrophage cholesterol efflux. J. Nutr. Biochem., 2008, 19, 514-23.
92. Vega-López, S.; Ausman, L.M.; Jalbert, S.M.; Erkkilä, A.T.; Lichtenstein, A.H. Palm and partailly hydrogenated soybean oils adversely alter lipoprotein profiles compared with soybean and canola oils in moderately hyperlipidemic subjects. Am. J. Clin. Nutr., 2006, 84, 54-62.
93. Fuhrman, B.; Plat, D.; Herzog, Y.; Aviram, M. Consumption of a novel dietary formula of plant sterol esters of canola oil fatty acids, in a canola oil matrix containing 1,3-diacylglycerol, reduces oxidative stress in atherosclerotic apolipoprotein E-deficient mice. J. Agric. Food Chem., 2007, 55, 2028-33.
94. Gordon, D.J.; Probstfield, J.L.; Garrison, R.J.; Neaton, J.D.; Castelli, W.P.; Knoke, J.D.; Jacobs, D.R. Jr.; Bangdiwala, S.; Tyroler, H.A. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation, 1989, 79, 8-15.
95. De Oliveira e Silva, E.R.; Foster, D.; McGee Harper, M.; Seidman, C.E.; Smith, J.D.; Breslow, J.L.; Brinton, E.A. Alcohol consump tion raises HDL cholesterol levels by increasing the transport rate of apolipoproteins A-I and A-II. Circulation, 2000, 102, 2347-52.
96. Rao, M.M.; Marmillot, P.; Gong, M.; Palmer, D.A.; Seeff, L.B.; Strader, D.B.; Lakshman, M.R. Light, but not heavy alcohol drinking, stimulates paraoxonase by upregulating liver mRNA in rats and humans. Metabolism, 2003, 52, 1287-94.
97. Marsillach, J.; Ferré, N.; Vila, M.C.; Lligoña, A.; Mackness, B.; Mackness, M.; Deulofeu, R.; Solá, R.; Parés, A.; Pedro-Botet, J.; Joven, J.; Caballeria, J.; Camps, J. Serum paraoxonase-1 in chronic alcoholics: relationship with liver disease. Clin. Biochem., 2007, 40, 645-50.
98. Dalgard, C. In The Paraoxonases: Their Role in Disease Development and Xenobiotic Metabolism; Mackness, Mackness, Aviram, Paragh, Eds.; Springer: Dordrecht, 2008, pp. 283-293.
99. Aviram, M.; Rosenblat, M.; Gaitini, D.; Nitecki, S.; Hoffman, A.; Dornfeld, L.; Volkova, N.; Presser, D.; Attias, J.; Liker, H.; Hayek, T. Pomegranate juice consumption for 3 years by patients with carotid stenosis reduces common carotid intima-media thickness, blood pressure and LDL oxidation. Clin. Nutr., 2004, 23, 423-33.
100. Hayek, T.; Fuhrman, B.; Vaya, J.; Rosenblat, M.; Belinky, P.; Coleman, R.; Elis, A.; Aviram, M. Reduced progression of atherosclerosis in apolipoprotein E-deficient mice following consumption of red wine, or its polyphenols quercetin or catechin, is associated with reduced susceptibility of LDL to oxidation and aggregation. Atheroscler. Thromb. Vasc. Biol., 1997, 17, 2744-52.
101. Aviram, M.; Dornfeld, L.; Rosenblat, M.; Volvoka, N.; Kaplan, M.; Coleman, R.; Hayek, T. Pomegranate juice consumption reduces oxidative stress, atherogenic modifications to LDL, and platelet aggregation: studies in humans and in atherosclerotic apolipoprotein E-deficient mice. Am. J. Clin. Nutr., 2000, 71, 1062-76.
102. 0) mice and in vitro in cultured macrophages and lipoproteins. J. Agric. Food Chem., 2008, 56, 1148-57
103. Gouédard, C.; Barouki, R.; Morel, Y. Induction of the paraoxonase-1gene expression by resveratrol. Arterioscler. Thromb. Vasc. Biol., 2004, 24, 2378-83.
104. Curtin, B.F.; Seetharam, K.I.; Dhoieam, P.; Gordon, R.K.; Doctor, B.P.; Nambiar, M.P. Resveratrol induces catalytic bioscavenger paraoxonase 1 expression and protects against chemical warfare nerve agent toxicity in human cell lines. J. Cell. Biochem., 2008, 103, 1524-35.
105. Do, G.M.; Kwon, E.Y.; Kim, H.J.; Jeon, S.M.; Ha, T.Y.; Park, T.; Choi, M.S. Long-term effects of resveratrol supplementation on suppression of atherogenic lesion formation and cholesterol synthesis in apo E-deficient mice. Biochem. Biophys. Res. Commun., 2008, 374, 55-9.
106. James, R.W.; Leviev, I.; Righetti, A. Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease. Circulation, 2000, 101, 2252-57.
107. Sen-Banerjee, A.; Siles, X.; Campos, H. Tobacco smoking modifies association between Gln-Arg192 polymorphism of human paraoxonase gene and risk of myocardial infarction. Arterioscler. Thromb. Vasc. Biol., 2000, 20, 2120-6.
108. Malin, R.; Loimaala, A.; Nenonen, A.; Mercuri, M.; Vuori, I.; Pasanen, M.; Oja, P.; Bond, G.; Koivula, T.; Lehtimäki, T. Relationship between high-density lipoprotein paraoxonase gene M/L55 polymorphism and carotid atherosclerosis differs in smoking and nonsmoking men. Metabolism, 2001, 50, 1095-101.
109. Nishio E.; Watanabe, Y. Cigarette smoke extract inhibits plasma paraoxonase activity by modification of the enzyme's free thiols. Biochem. Biophys. Res. Commun., 1997, 236, 289-93.
110. Sutherland, W.H.F.; Walker, R.J.; de Jong, S.A.; van Rij, A.M., Phillips, V.; Walker, H.L. Reduced postprandial serum paraoxonase activity after a meal rich in used cooking fat. Arterioscler. Thromb. Vasc. Biol., 1999, 19, 1340-7.
111. Scott Rector, R.; Warner, S.O.; Liu, Y.; Hinton, P.S.; Sun, G.Y.; Cox, R.H.; Stump, C.S.; Harold Laughlin, M.; Dellsperger, K.C.; Thomas, T.R. Exercise and diet induced weight loss improves measures of oxidative stress and insulin sensitivity in adults with cahracteristics of the metabolic syndrome. Am. J. Physiol. Endocrinol. Metab., 2007, 293, E500-6.
112. Tsakiris, S.; Karikas, G.A.; Parthimos, T.; Tsakiris, T.; Bakogiannis, C.; Schulpis, K.H. Alpha-tocopherol supplementation prevents the exercise-induced reduction of serum paraoxonase 1/arylesterase activities in healthy individuals. Eur. J. Clin. Nutr., 2009, 63, 215-21.